Neurosteroids as neuromodulators in the treatment of anxiety disorders
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Anxiety disorders are the most common psychiatric disorders. They are frequently treated with benzodiazepines, which are fast acting highly effective anxiolytic agents. However, their long-term use is impaired by tolerance development and abuse liability. In contrast, antidepressants such as selective serotonin reuptake inhibitors (SSRIs) are considered as first-line treatment but have a slow onset of action. Neurosteroids are powerful allosteric modulators of GABA(A) and glutamate receptors. However, they also modulate sigma receptors and they are modulated themselves by SSRIs. Both pre-clinical and clinical studies have shown that neurosteroid homeostasis is altered in depression and anxiety disorders and antidepressants may act in part through restoring neurosteroid disbalance. Moreover, novel drugs interfering with neurosteroidogenesis such as ligands of the translocator protein (18 kDa) may represent an attractive pharmacological option for novel anxiolytics which lack the unwarranted side effects of benzodiazepines. Thus, neurosteroids are important endogenous neuromodulators for the physiology and pathophysiology of anxiety and they may constitute a novel therapeutic approach in the treatment of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225 · cited 2×
“While 3α, 5α-THP binds to GABAA receptors thereby increasing the time and frequency of the opening of the Clchannel (Majewska et al., 1986), pregnenolone sulfate (PREGS) has been described as both a positive NMDA receptor modulator (Figure 3B; Kussius et al., 2009) and negative GABAA receptor modulator (Mtchedlishvili…”
BackgroundThe Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · cited 2×
“…and anxiety and the observation that both drugs cause an elevation of extracellular monoamine levels by blocking monoamine oxidase (MAO) or inhibiting the neuronal serotonin and/or noradrenaline transporter led to the hypothesis of a “monoamine deficiency” in affective disorders (Coppen, 1967).”
BackgroundRupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T. C., Fan, J., Akula, N., Groyer, G., Adams, D., & Schumacher, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3295 · Cited by 930 · cited 3×
“Following cholesterol translocation, pregnenolone, and ring Areduced neurosteroids are synthesized, which in turn may enhance GABA-mediated neurotransmission (Rupprecht and Holsboer, 1999; Rupprecht et al., 2010).”
BackgroundNeurosteroids: biosynthesis and function of these novel neuromodulators
Compagnone, N. A., & Mellon, S. H. (2000) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0188 · Cited by 820 · cited 3×
“Also the isomer 3α, 5β-THP exerts a comparable positive modulation of GABAA receptors (Baulieu et al., 2001).”
BackgroundRegulation of the hypothalamic corticotropin-releasing hormone neurosecretory system
Whitnall, M. H. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90035-q · Cited by 582 · cited 1×
“Thus, DHEA and DHEA sulfate rapidly activate the HPA axis through sigma-1 receptors as well as GABAA and NMDA receptors which also control the HPA axis activity (Whitnall, 1993).”
BackgroundGABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 2×
“Moreover, BDZs are potent positive allosteric modulators of the GABAA receptors (Rudolph and Möhler, 2006).”
BackgroundMonnet, F. P., Mahé, V, Robel, P., & Baulieu, E. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3774 · Cited by 429 · cited 1×
“Specifically, while pregnenolone, dehydroepiandrosterone (DHEA) and their sulfate esters act as agonists of the sigma-1 receptors, progesterone acts as a potent antagonist (Monnet et al., 1995; Bergeron and Debonnel, 1997; Maurice and Privat, 1997).”
BackgroundNeuroactive steroids: mechanisms of action and neuropsychopharmacological properties
Rupprecht, R. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00064-1 · Cited by 427
Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes
Griffin, L. D., & Mellon, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13512 · Cited by 387 · cited 1×
“Moreover, Griffin and Mellon (1999) demonstrated that fluoxetine is able to increase 3α, 5α-THP production by increasing the reduction of its precursor 5α-dihydroprogesterone (5α-DHP) via a direct interference with the 3α-hydroxysteroid oxidoreductase.”
BackgroundTranslocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects
Rupprecht, R., Rammes, G., Eser, D., Baghai, T. C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H. O., Chaperon, F., et al. (2009) · Science · doi:10.1126/science.1175055 · Cited by 328
Serotonin: a regulator of neuronal morphology and circuitry
Daubert, E. A., & Condron, B. G. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.005 · Cited by 326 · cited 2×
“It is a metabolite of l-tryptophan, converted to 5- hydroxytryptophan (5-HTP) by the tryptophan hydroxylase, and thereafter immediately decarboxylated to serotonin by the aromatic l-amino acid decarboxylase (Strüder and Weicker, 2001a,b; Daubert and Condron, 2010).”
BackgroundDong, E., Matsumoto, K., Uzunova, V., Sugaya, I., Takahata, H., Nomura, H., Watanabe, H., Costa, E., & Guidotti, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628598 · Cited by 261
Pinna, G., Costa, E., & Guidotti, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0213-2 · Cited by 245 · cited 3×
“side effects caused by direct systemic administration of NS (Pinna et al., 2006).”
BackgroundInfluentialNikolaus, S., Antke, C., Beu, M., & Müller, H.-W. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.2.119 · Cited by 243 · cited 1×
“GABAA receptors are one of the most important targets for the treatment of anxiety symptoms, because reduced GABAA receptor function may be related to the pathophysiology of anxiety (Nikolaus et al., 2010).”
BackgroundGABA: homeostatic and pharmacological aspects
Schousboe, A., & Waagepetersen, H. S. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(06)60002-2 · Cited by 121 · cited 6×
“The term “neurosteroids” (NS), a term introduced by Baulieu (Baulieu and Robel, 1990; Paul and Purdy, 1992; Compagnone and Mellon, 2000), indicates steroids that modulate the action of the central nervous system (CNS), thereby regulating synaptic transmission at different targets (rapid non-genomic effect on presynapt…”
BackgroundInfluential
Cited by
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Sartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Fedotova, J., Kubatka, P., Büsselberg, D., Shleikin, A. G., Caprnda, M., Dragasek, J., Rodrigo, L., Pohanka, M., Gasparova, I., Nosal, V., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.107 · Cited by 59
Anxiolytics targeting GABA A receptors: Insights on etifoxine
Poisbeau, P., Gazzo, G., & Calvel, L. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1468030 · Cited by 47
Metadata
- Authors
- Longone, P.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 2
- Pages
- 55-55
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W1970144357
- Cited by
- 55
- References
- 16
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.